SF 730

2nd Engrossment - 90th Legislature (2017 - 2018) Posted on 03/16/2018 02:59pm

A bill for an act
relating to health; establishing an opiate stewardship program; appropriating money;
requiring a report; amending Minnesota Statutes 2016, sections 151.065, by adding
a subdivision; 151.252, subdivision 1; proposing coding for new law in Minnesota
Statutes, chapter 151.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2016, section 151.065, is amended by adding a subdivision
to read:

new text begin Subd. 3a. new text end

new text begin Stewardship fee. new text end

new text begin (a) In addition to the annual renewal fee specified under
subdivision 3, any drug manufacturer licensed under section 151.252 that sells opiates listed
under section 152.02, subdivision 3, paragraph (b) or (c), in this state shall pay an annual
stewardship fee.
new text end

new text begin (b) Annually by March 1, beginning March 1, 2018, a manufacturer must report to the
board the quantity of each opiate listed in section 152.02, subdivision 3, paragraphs (b) and
(c), that the manufacturer sold in the state in the previous calendar year. The board shall
use the information in the report to calculate the stewardship fee for each manufacturer.
The stewardship fee shall be equal to one cent per morphine milligram equivalent of opiates
listed in section 152.02, subdivision 3, paragraphs (b) and (c). The board shall use a morphine
equivalent chart published by the Centers for Disease Control and Prevention or another
reputable source to calculate morphine equivalents. If there is no commonly accepted
morphine equivalent for an opiate in a manufacturer's report, the board shall determine an
appropriate conversion based on its knowledge and expertise and shall notify the
manufacturer of the conversion value and method.
new text end

new text begin (c) The stewardship fees received by the board under this subdivision shall be deposited
in the state treasury and credited to the opiate stewardship account established under section
151.255.
new text end

Sec. 2.

Minnesota Statutes 2016, section 151.252, subdivision 1, is amended to read:

Subdivision 1.

Requirements.

(a) No person shall act as a drug manufacturer without
first obtaining a license from the board and paying any applicable fee specified in section
151.065.

(b) Application for a drug manufacturer license under this section shall be made in a
manner specified by the board.

(c) No license shall be issued or renewed for a drug manufacturer unless the applicant
agrees to operate in a manner prescribed by federal and state law and according to Minnesota
Rules.

(d) No license shall be issued or renewed for a drug manufacturer that is required to be
registered pursuant to United States Code, title 21, section 360, unless the applicant supplies
the board with proof of registration. The board may establish by rule the standards for
licensure of drug manufacturers that are not required to be registered under United States
Code, title 21, section 360.

(e) No license shall be issued or renewed for a drug manufacturer that is required to be
licensed or registered by the state in which it is physically located unless the applicant
supplies the board with proof of licensure or registration. The board may establish, by rule,
standards for the licensure of a drug manufacturer that is not required to be licensed or
registered by the state in which it is physically located.

(f) The board shall require a separate license for each facility located within the state at
which drug manufacturing occurs and for each facility located outside of the state at which
drugs that are shipped into the state are manufactured.

(g) The board shall not issue an initial or renewed license for a drug manufacturing
facility unless the facility passes an inspection conducted by an authorized representative
of the board. In the case of a drug manufacturing facility located outside of the state, the
board may require the applicant to pay the cost of the inspection, in addition to the license
fee in section 151.065, unless the applicant furnishes the board with a report, issued by the
appropriate regulatory agency of the state in which the facility is located or by the United
States Food and Drug Administration, of an inspection that has occurred within the 24
months immediately preceding receipt of the license application by the board. The board
may deny licensure unless the applicant submits documentation satisfactory to the board
that any deficiencies noted in an inspection report have been corrected.

new text begin (h) The board shall not renew the license of any drug manufacturer that is required to
pay the stewardship fee under section 151.065, subdivision 3a, unless the drug manufacturer
pays the board the required fee in accordance with section 151.065, subdivision 3a.
new text end

Sec. 3.

new text begin [151.255] OPIATE PRODUCT STEWARDSHIP.
new text end

new text begin Subdivision 1. new text end

new text begin Establishment of the advisory council. new text end

new text begin (a) The Opiate Product
Stewardship Advisory Council is established to confront the opioid addiction and overdose
epidemic in this state and focus on:
new text end

new text begin (1) prevention and education, including public education and awareness for adults and
youth, prescriber education, and the development and sustainability of opioid overdose
prevention programs;
new text end

new text begin (2) a continuum of care for opioid-related substance use disorders that expands and
enhances all modalities of treatment from detox to sober housing; and
new text end

new text begin (3) services to ensure overdose prevention as well as public safety and community
well-being, including expanding access to naloxone and providing social services to families
affected by the opioid overdose epidemic.
new text end

new text begin (b) The council shall:
new text end

new text begin (1) review local, state, and federal initiatives and activities related to education,
prevention, and services for individuals and families experiencing and affected by opioid
abuse;
new text end

new text begin (2) establish priorities and actions to address the state's opioid epidemic for the purpose
of allocating funds;
new text end

new text begin (3) ensure optimal allocation of available funding and alignment of existing state and
federal funding to achieve the greatest impact and ensure a coordinated state effort;
new text end

new text begin (4) develop criteria and procedures to be used in awarding grants and allocating available
funds from the opiate stewardship account; and
new text end

new text begin (5) develop measurable outcomes to determine the effectiveness of the funds allocated
under this section.
new text end

new text begin (c) The council shall make recommendations on possible grant and funding options for
the funds annually appropriated to the commissioner of human services from the opiate
stewardship account. The options for funding may include prescriber education, the
development and sustainability of prevention programs, the creation of a continuum of care
for opioid-related substance abuse disorders from detox to sober houses, and additional
funding for child protection case management services for children and families affected
by opioid addiction.
new text end

new text begin (d) The council shall submit recommendations for possible funding options to the chairs
and ranking minority members of the legislative committees with jurisdiction over health
and human services policy and finance by March 1 of each year beginning March 1, 2019.
new text end

new text begin Subd. 2. new text end

new text begin Membership. new text end

new text begin (a) The council shall consist of 18 members appointed by the
commissioner of human services, except as otherwise specified:
new text end

new text begin (1) two members of the house of representatives, one from the majority party appointed
by the speaker of the house and one from the minority party appointed by the minority
leader;
new text end

new text begin (2) two members of the senate, one from the majority party appointed by the senate
majority leader and one from the minority party appointed by the senate minority leader;
new text end

new text begin (3) one member appointed by the Board of Pharmacy;
new text end

new text begin (4) one member appointed by the Minnesota chapter of the American College of
Emergency Physicians who is a medical doctor;
new text end

new text begin (5) one member representing opioid treatment facilities or sober living facilities;
new text end

new text begin (6) one member who is a medical doctor appointed by the Minnesota Hospital
Association;
new text end

new text begin (7) one member who is a medical doctor appointed by the Minnesota Society of Addiction
Medicine;
new text end

new text begin (8) one member representing a pain psychologist;
new text end

new text begin (9) one member appointed by the Steve Rummler Hope Network;
new text end

new text begin (10) one member appointed by the Minnesota Ambulance Association;
new text end

new text begin (11) one member representing the Minnesota courts who is a judge or law enforcement
officer;
new text end

new text begin (12) one public member who is a Minnesota resident and who has been impacted by the
opioid epidemic;
new text end

new text begin (13) one member representing a manufacturer of opiates;
new text end

new text begin (14) one member representing an Indian tribe;
new text end

new text begin (15) the commissioner of human services or designee; and
new text end

new text begin (16) the commissioner of health or designee.
new text end

new text begin (b) Except for section 15.059, subdivisions 2 and 3, section 15.059 shall apply to the
public members of the council and all the council member appointments, except those
members who are commissioners or their designees or legislators. The members of the
council shall receive no compensation other than reimbursement for expenses.
Notwithstanding section 15.059, subdivision 6, the council shall not expire. The
commissioner of human services shall designate eight of the public members to serve terms
that are coterminous with the governor and eight public members to serve terms that end
on the first Monday in January one year after the terms of the other members. Legislators
serve until a replacement is appointed.
new text end

new text begin (c) The chair must convene the council at least quarterly, and may convene other meetings
as deemed necessary.
new text end

new text begin (d) The commissioner of human services shall provide staff for administrative services
for the advisory council.
new text end

new text begin (e) The council shall be subject to chapter 13D.
new text end

new text begin Subd. 3. new text end

new text begin Dedicated account. new text end

new text begin (a) The opiate stewardship account is created in the special
revenue fund in the state treasury. The fees collected by the Board of Pharmacy under section
151.065, subdivision 3a, shall be deposited in the account.
new text end

new text begin (b) In fiscal year 2018, money in the account is appropriated to the commissioner of
human services to be allocated in accordance with section 4.
new text end

new text begin (c) Beginning July 1, 2019, and each fiscal year thereafter, money in the account shall
be appropriated to the commissioner of human services to be awarded as grants as determined
appropriate to address the opioid epidemic in the state.
new text end

Sec. 4. new text begin OPIOID ABUSE PREVENTION GRANTS FOR FISCAL YEAR 2018.
new text end

new text begin Subdivision 1. new text end

new text begin Opioid prescriber education and public awareness grants. new text end

new text begin For fiscal
year 2018, from the funds appropriated to the commissioner of human services from the
opioid stewardship account established in Minnesota Statutes, section 151.255, subdivision
3, the commissioner of human services shall award up to $1,000,000 in grants to nonprofit
organizations for the purpose of expanding prescriber education, public awareness and
outreach on the opioid epidemic and overdose prevention programs. The grantees must
coordinate with health care systems, professional associations, and emergency medical
services providers. Each grantee receiving funds under this paragraph shall report to the
commissioner of human services and the Opiate Product Stewardship Advisory Council on
how the funds were spent and the outcomes achieved.
new text end

new text begin Subd. 2. new text end

new text begin County social services. new text end

new text begin For fiscal year 2018, $15,000,000 of the funds
appropriated to the commissioner of human services from the opiate stewardship account
established in Minnesota Statutes, section 151.255, subdivision 3, shall be used for county
social services agencies to provide services to children in placement who are affected by
opioid addiction. The commissioner shall distribute the money allocated under this
subdivision proportionally to counties based on the number of open child protection case
management cases in the county using data from the previous calendar year.
new text end

new text begin Subd. 3. new text end

new text begin Pilot projects. new text end

new text begin (a) For fiscal year 2018, from the funds appropriated to the
commissioner of human services from the opiate stewardship account in Minnesota Statutes,
section 151.255, subdivision 3, the commissioner of human services shall transfer $2,500,000
to the commissioner of health to establish up to 12 opioid abuse prevention pilot projects.
new text end

new text begin (b) Each pilot project must:
new text end

new text begin (1) be designed to reduce emergency room and other health care provider visits resulting
from opioid use or abuse, and reduce rates of opioid addiction in the community;
new text end

new text begin (2) establish multi-disciplinary controlled substance care teams, that may consist of
physicians, pharmacists, social workers, nurse care coordinators, and mental health
professionals;
new text end

new text begin (3) deliver health care services and care coordination, through controlled substance care
teams, to reduce the inappropriate use of opioids by patients and rates of opioid addiction;
new text end

new text begin (4) address any unmet social service needs that create barriers to managing pain
effectively and obtaining optimal health outcomes;
new text end

new text begin (5) provide prescriber and dispenser education and assistance to reduce the inappropriate
prescribing and dispensing of opioids;
new text end

new text begin (6) promote the adoption of best practices related to opioid disposal and reducing
opportunities for illegal access to opioids; and
new text end

new text begin (7) engage partners outside of the health care system, including schools, law enforcement,
and social services, to address root causes of opioid abuse and addiction at the community
level.
new text end

new text begin (c) The commissioner shall contract with an accountable community for health that
operates an opioid abuse prevention project, and can document success in reducing opioid
use through the use of controlled substance care teams, to assist the commissioner in
administering this section, and to provide technical assistance to the commissioner and to
entities selected to operate a pilot project.
new text end

new text begin (d) The contract under paragraph (c) shall require the accountable community for health
to evaluate the extent to which the pilot projects were successful in reducing the inappropriate
use of opioids. The evaluation must analyze changes in the number of opioid prescriptions,
the number of emergency room visits related to opioid use, and other relevant measures.
The accountable community for health shall report evaluation results to the chairs and
ranking minority members of the legislative committees with jurisdiction over health and
human services policy and finance and public safety, by December 15, 2019.
new text end

new text begin Subd. 4. new text end

new text begin Board of Pharmacy. new text end

new text begin For fiscal year 2018, from the funds appropriated to the
commissioner of human services from the opiate stewardship account in Minnesota Statutes,
section 151.255, subdivision 3, the commissioner shall transfer $50,000 to the Board of
Pharmacy to be used for system changes needed to collect the stewardship fee specified in
Minnesota Statutes, section 151.065, subdivision 3a.
new text end

Sec. 5. new text begin OPIATE PRODUCT STEWARDSHIP ADVISORY COUNCIL FIRST
MEETING.
new text end

new text begin The commissioner of human services shall convene the first meeting of the Opiate
Product Stewardship Advisory Council no later than October 1, 2017. The members shall
elect a chair at the first meeting.
new text end